Huang, Q., An, Z., Zhao, P., Chen, Q., Wu, J., Fu, H., Dong, Y., Jing, H., Dou, L., Liu, H., Liu, Y., Xu, L., Huang, X., Zhang, X. (2025). Iguratimod plus low-dose rituximab as second-line treatment in adults with primary immune thrombocytopenia: A multicenter, open-label, randomized, controlled, Phase 2 trial. Blood. https://doi.org/10.1182/blood-2025-3044